<?xml version="1.0" encoding="UTF-8"?>
<p id="Par38">SLE is the prototype of the autoimmune diseases. And, the main risk factor seems like the immunosuppressive therapies we use in SLE treatment. However, Sawalha et al. reported that epigenetic dysregulation in SLE resulted in ACE2 overexpression, and this might cause a specific tendency to COVID-19 in this patient group [
 <xref ref-type="bibr" rid="CR101">101</xref>]. Another debate in the literature focused on the hypothetical prophylactic effect of HCQ, which is used by a majority of SLE patients (discussed below).
</p>
